Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × HER-2 Positive Breast Cancer × Trastuzumab × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 266 Stomach Neoplasms 31 Neoplasm Metastasis 21 Neoplasms 15 Breast Neoplasms, Male 14 Colorectal Neoplasms 13 HER2-positive Breast Cancer 11 Triple Negative Breast Neoplasms 8 Esophageal Neoplasms 8 Inflammatory Breast Neoplasms 7 Brain Neoplasms 7 Rectal Neoplasms 6 Adenocarcinoma 6 Pathologic Complete Response 5 Colonic Neoplasms 5 Carcinoma, Non-Small-Cell Lung 5 Salivary Gland Neoplasms 4 Gallbladder Neoplasms 4 Biliary Tract Neoplasms 4 Urologic Neoplasms 3 Urinary Bladder Neoplasms 3 Recurrence 3 Neoplastic Cells, Circulating 3 Meningeal Neoplasms 3 Cholangiocarcinoma 3 Carcinoma, Ductal, Breast 3 Sarcoma 2 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Osteosarcoma 2

Interventions

liposomal doxorubicin 1 Trastuzumab 1 Metformin 1 Doxorubicin 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02488564 2025-02-03

met-HEReMYTA

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Completed

HER-2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡